Beijing Hotgen Biotech Co. Ltd. Class A

As of June 30, 2026, Beijing Hotgen Biotech Co. Ltd. Class A carries a market capitalization of 8.03B, placing it among publicly traded companies globally. Its enterprise value stands at 6.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Beijing Hotgen Biotech Co. Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Beijing Hotgen Biotech Co. Ltd. Class A has 92.75M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Beijing Hotgen Biotech Co. Ltd. Class A maintains a current ratio of 8.13, meaning it holds 8.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Beijing Hotgen Biotech Co. Ltd. Class A recorded an income tax benefit of -7.79M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 23, 2026, Beijing Hotgen Biotech Co. Ltd. Class A's stock has declined approximately 56.22% over the past 52 weeks. The 50-day moving average sits at 93.05, while the 200-day moving average is 114.71.

As of June 30, 2026, Beijing Hotgen Biotech Co. Ltd. Class A holds 1.20B in cash and equivalents against 98,455.76 in total debt, resulting in a net debt position of -216.38M. Total book value stands at 2.44B, with working capital of 1.28B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Beijing Hotgen Biotech Co. Ltd. Class A paid dividends of 0.01 per share.

Beijing Hotgen Biotech Co. Ltd. Class A's most recent stock split took place on June 16, 2022 with a 25:37 split ratio.